### Analysis
Amgen's Q3 earnings call highlighted strong volume growth and record sales for several key products, particularly in the international market. The company's focus on innovation and pipeline development was evident, with notable advancements in biosimilars and new therapies. However, there were some concerns about potential market competition and pricing dynamics, especially for biosimilars. The company's guidance for 2022 was updated to reflect FX headwinds and the impact of the ChemoCentryx acquisition. Despite these challenges, the company remains optimistic about its long-term growth prospects.

### Conclusion
The short-term impact on Amgen's stock is likely to be neutral to slightly positive, given the company's strong performance in the quarter and its continued pipeline development. However, the stock may face some temporary pressure due to the challenges posed by market competition and pricing dynamics for biosimilars. The overall outlook remains positive, with the company well-positioned for long-term growth.

### Rating
[1]